Page last updated: 2024-10-24

endonucleolytic cleavage in ITS1 to separate SSU-rRNA from 5.8S rRNA and LSU-rRNA from tricistronic rRNA transcript (SSU-rRNA, 5.8S rRNA, LSU-rRNA)

Definition

Target type: biologicalprocess

Endonucleolytic cleavage between the SSU-rRNA and the 5.8S rRNA of an rRNA molecule originally produced as a tricistronic rRNA transcript that contained the Small SubUnit (SSU) rRNA, the 5.8S rRNA, and the Large SubUnit (LSU) rRNA, in that order, from 5' to 3' along the primary transcript. [GOC:curators, PMID:10690410]

The tricistronic rRNA transcript, containing the small subunit ribosomal RNA (SSU-rRNA), 5.8S ribosomal RNA (5.8S rRNA), and large subunit ribosomal RNA (LSU-rRNA), is initially synthesized as a single precursor molecule. This precursor undergoes a series of processing steps, including endonucleolytic cleavage, to generate mature rRNA molecules. One critical endonucleolytic cleavage event occurs within the internal transcribed spacer 1 (ITS1) region, which separates the SSU-rRNA from the 5.8S rRNA and LSU-rRNA. This cleavage is mediated by specific endonucleases, often termed ribonucleases (RNases), which recognize and cleave the RNA at specific sequences within the ITS1. The precise sequence targeted by the RNases can vary depending on the organism. Following cleavage, the SSU-rRNA is released from the precursor molecule, while the 5.8S rRNA and LSU-rRNA remain linked. Further processing steps, including additional endonucleolytic cleavages and exonucleolytic trimming, are required to generate mature 5.8S rRNA and LSU-rRNA molecules.'
"

Proteins (1)

ProteinDefinitionTaxonomy
40S ribosomal protein S21A small ribosomal subunit protein eS21 that is encoded in the genome of human. [PRO:DNx, UniProtKB:P63220]Homo sapiens (human)

Compounds (2)

CompoundDefinitionClassesRoles
gentamicin sulfate
PF-06446846PF-06446846 : A triazolopyridine that is 3H-[1,2,3]triazolo[4,5-b]pyridine substituted by a 4-{(3-chloropyridin-2-yl)[(3R)-piperidin-3-yl]carbamoyl}phenyl group at position 3. It is a potent inhibitor of PCSK9.

PF-06446846: inhibits translation of PCSK9 ;structure in first source
benzamides;
monochloropyridine;
piperidines;
tertiary carboxamide;
triazolopyridine
antilipemic drug;
EC 3.4.21.61 (kexin) inhibitor